FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating enterprise-wide visibility and connectivity that transforms data into actionable insight.
"Our vision for the BD Incada™ Platform is to go beyond legacy connectivity to create meaningful connections across devices from infusion pumps to patient monitors to pharmacy robotics, and unify data from those solutions into one ecosystem, transforming data into clear, actionable insights for care teams," said Bilal Muhsin, EVP and President of BD Connected Care. "These launches represent key milestones in BD's Connected Care strategy, where we are uniquely positioned with our broad portfolio from pharmacy to bedside, to leverage game-changing technology to drive meaningful benefits for our customers."
AI-powered analytics to drive smarter, faster decisions
Built on Amazon Web Services' (AWS) on-demand cloud computing infrastructure, the BD Incada™ Platform leverages the latest in AI technologies, such as natural language search in analytics, and is scalable to meet the data volumes created by nearly 3 million smart connected BD devices. With Analytics in the BD Incada™ Platform, data from BD's leading medication management solutions now flows through a secure, cloud platform and enables:
Flexible, secure storage to get the right medication to the right patient, faster
The new BD Pyxis™ Pro Dispensing Solution delivers smarter, more secure medication storage, which enables faster access at the point of care. The first-of-its-kind flexible, stackable device configuration offers more medication storage capacity to improve medication availability from refrigerated to ambient storage. The BD Pyxis™ Pro Dispensing Solution allows hospitals and health systems to easily adapt to the evolving needs of their patient populations, with features including:
"For over 35 years, the BD Pyxis™ System has been the backbone of medication management across hospitals and health systems, with more than 9.8 million transactions on BD Pyxis™ devices every day," said Connor Bates, Worldwide President for Medication Management Solutions at BD. "With the enhanced secure capacity, durability and AI-powered analytics of the next-generation BD Pyxis™ Pro Dispensing Solution, we're ushering in a transformative new era for medication management."
Together, the BD Incada™ Platform and BD Pyxis™ Pro Dispensing Solution sets a new standard for unified, data-driven healthcare operations.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiency, improve safety, and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$191.00 |
Daily Change: | 1.90 1.00 |
Daily Volume: | 1,431,930 |
Market Cap: | US$54.750B |
October 08, 2025 September 22, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load